UAE registers China's Sinopharm vaccine, says 86% effective

The vaccine has been undergoing third-phase trials in the Emirates since July, and it was approved for emergency use for health care workers in September.

December 09, 2020 01:29 pm | Updated 10:04 pm IST - Dubai

A model of a coronavirus is displayed next to boxes for COVID-19 vaccines at an exhibit by Chinese pharmaceutical firm Sinopharm at the China International Fair for Trade in Services (CIFTIS) in Beijing, Saturday, Sept. 5, 2020.

A model of a coronavirus is displayed next to boxes for COVID-19 vaccines at an exhibit by Chinese pharmaceutical firm Sinopharm at the China International Fair for Trade in Services (CIFTIS) in Beijing, Saturday, Sept. 5, 2020.

The United Arab Emirates on Wednesday officially registered the coronavirus vaccine produced by Chinese drug giant Sinopharm, saying it was 86% effective according to analysis of third-phase trials.

Also read:Bahrain now second nation to grant Pfizer shot emergency use

The health ministry “has announced the official registration” of the vaccine, state news agency WAM said, without elaborating on how it would now be used.

The vaccine has been undergoing third-phase trials in the Emirates since July, and it was approved for emergency use for health care workers in September.

“The announcement is a significant vote of confidence by the UAE's health authorities in the safety and efficacy of this vaccine,” WAM said.

UAE health officials have reviewed Sinopharm's interim analysis of the third-phase trials which shows it is 86% percent effective against coronavirus, the report said.

“The analysis also shows the vaccine to have 99% seroconversion rate of neutralising antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease. Furthermore, the analysis shows no serious safety concerns.”

China has four vaccine products in the final stages of development, three of which — including Sinopharm — use an inactivated form of the novel coronavirus to boost immunity.

This means they only need to be refrigerated and can be easily distributed compared to jabs developed by rivals Pfizer and BioNTech or Moderna, which have reported efficacy of 95% and 94% respectively but need to be transported at minus 70 to 20 degrees Celsius.

However, Chinese drugmakers have not released any data on their vaccines' safety or efficacy.

Also read:Almost a million inoculated in China, Sinopharm

Chinese vaccine makers also have chequered reputations, after major scandals at home involving expired or poor quality products. While the government's domestic handling of the virus has won support within China, overseas buyers are cautious.

Chinese vaccine frontrunners Sinovac and Sinopharm have pre-orders for less than 500 million doses in total by mid-November, according to data from London consultancy Airfinity, mostly from countries that have participated in trials.

Two vaccines have undergone third-phase trials in the UAE, the Sinopharm project and Russia's Sputnik-V, named after the Soviet-era satellite.

Dubai ruler Sheikh Mohammed bin Rashid Al-Maktoum said in November that he had received an experimental coronavirus vaccine, joining other top UAE officials to take part in the trials.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.